Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an autoimmune disorder characterized by the progressive damage to the peripheral nerves, leading to weakness and sensory loss.

79 CIDP is a rare heterogenous disease with complex pathophysiology and diagnosis, and few treatment options. Despite these obstacles, substantial gains have been made by dedicated experts in the ...

"Biomarkers can be challenging to understand in CIDP because of the rarity and heterogeneity of the disease," said Jeffrey ...

Chronic inflammatory demyelinating polyneuropathy is an immune-mediated neuropathy that affects the peripheral motor and sensory nerves. The symptoms are of a slowly progressive numbness and tingling ...

Vyvgart Hytrulo (efgartigimod alfa/hyaluronidase) is the first drug in the FcRn blocker class to treat CIDP, a rare autoimmune disease of the peripheral nervous system that causes fatigue ...

Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug t ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic immune-mediated neuropathy. It affects peripheral nerves and roots. CIDP has no biomarkers. It may be monophasic ...

Background: Chronic inflammatory demyelinating polyradiculoneuropathy is a rare acquired immune-mediated progressive or relapsing disorder causing peripheral neuropathic disease of duration more ...

THE family of a "beloved father and husband" who took his own life after Covid-19 vaccine complications are fighting for justice.

and those with obvious underlying secondary CIDP etiologies including diabetes, autoantibodies, or an IgM monoclonal gammopathy. Patients with hypertension, other medical disorders preventing ...

(RTTNews) - argenx SE (ARGX) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) approved VYVDURA for adults with chronic inflammatory demyelinating polyneuropathy. VYVDURA is ...